Document:

Exhibit 10.5 

 

CHIEF FINANCIAL OFFICER AGREEMENT

 

This Chief Financial Officer Agreement
(this “Agreement”) is made and entered into as of the   28th   day of October 2013 by and between American
Doctors Online, Inc., a Delaware corporation (the “Company”) and Venture Equity, LLC.(“Venture Equity”)
and Barry Hollander (collectively, the “CFO“).

 

WITNESSETH

WHEREAS, the Company
has previously engaged Venture Equity as a financial consultant.

 

WHEREAS, Mr. Barry
Hollander is the sole member of Venture Equity.

 

WHEREAS, pursuant
to the engagement Venture Equity is compensated $5,000 on a monthly basis and the Company had agreed to issue two percent (2%)
(the :Initial Equity Consideration”) of the Company’s common stock to Venture Equity.

 

WHEREAS, Mr. Hollander
has previously accepted being named to the board of directors and is now accepting being named Chief Financial Officer of the Company.
As compensation for these additional duties, the Company has agreed to issue an additional three percent (3%) equity compensation,
to Mr. Hollander, to serve as the CFO for no less than one year.

 

NOW, THEREFORE, in consideration
of the promises and mutual covenants contained herein, the parties, intending to be legally bound, agree as follows:

AGREEMENT

1. Engagement as CFO

1.1 Effective Date. CFO’s
engagement by the Company pursuant to this Agreement will commence on November 1, 2013 (the “Effective Date“).

1.2 Term of Engagement. CFO’s
engagement by the Company pursuant to this Agreement will be for a period of one year (the “Term” of the Agreement).
In the final year of the Term, the parties shall discuss and negotiate in good a possible extension of the Term. The parties may
extend the Term from time to time by mutual agreement. Notwithstanding the foregoing, the CFO‘s engagement may be terminated
pursuant to Section 3 of this Agreement.

1.3 Duties of CFO. The Board
of Directors (“Board“) has appointed the CFO. CFO will have and fulfil such duties and responsibilities as may
be established by the Board in its sole discretion. CFO will devote part of his working time, attention, and energy to the Company’s
business and the Parties agree that during the Term of this Agreement the CFO is permitted to engage in any outside business or
other activity unrelated to serving the Company’s interest. CFO will fulfil his duties and responsibilities as described
in this section in a reasonable and appropriate manner in light of the Company’s policies and practices as reasonably established
by the Company and the laws and regulations which apply to the Company’s operation and administration.

1.4 Location. CFO shall perform
his duties at the office of Venture Equity, his home office or at any alternate location(s) as may reasonably be required pursuant
to the duties set forth herein, and as may be directed from time to time by the Board or a committee thereof; or by the CEO of
the Company.

2. Compensation and Benefits

2.1 Salary and Bonus. Commencing
in November 2013, the Company will pay the CFO at an monthly rate of $5,000. Thereafter the salary will be as set by the Board,
and the CFO shall be eligible for quarterly bonuses pursuant to an incentive compensation plan that will be devised by the Board
or by its compensation committee.

2.2 Equity Compensation. The Company
will issue to the CFO a total of five percent (5%) of the outstanding common stock (the “Equity Consideration”) of
the Company. The Equity Consideration includes the Initial Equity Consideration. If the CFO is not engaged by the Company on the
six month anniversary of the Effective Date, the CFO will return three percent (3%) of the Equity Consideration. If the CFO is
not engaged by the Company on the one year anniversary from the Effective Date, the CFO will return one and one-half percent (1.5%)
of the Equity Consideration.

2.3 Vacation and Benefits.
CFO shall be provided two weeks of vacation annually and other benefits at a level consistent with that provide to other senior
CFOs of the Company.

2.4Business Expenses. CFO
shall be entitled to reimbursement for all reasonable business related expenses incurred by CFO at the request of or on behalf
of the Company, upon the submission of adequate documentation of such expenses and subject to the Company’s policies and
procedures.

3. Termination

3.1 Termination. This Agreement
and CFO’s engagement with the Company shall terminate as follows:

a. By the Company.

i.For Good Cause.
The Company may terminate this Agreement and CFO’s engagement with the Company at any time for Good Cause (“Good
Cause Termination“). For purposes of this Agreement, the term “Good Cause“ shall mean: (i) unauthorized use
or disclosure of the Confidential Information or Trade Secrets of the Company; (ii) any material breach of this Agreement (including
Sections 4 and 5) (iii) conviction of, or plea of “guilty“ or “no contest“ to, a felony under the laws
of the United States or any state thereof; (iv) misappropriation of the assets of the Company or other acts of dishonesty which
have a material adverse effect on the Company or its assets; (v) for repeated wilful misconduct or gross negligence in the performance
of duties assigned to the CFO under this Agreement after having received a written notice of such misconduct or gross negligence
from the Board or a committee thereof; (vi) failure to perform reasonable duties assigned to the CFO under this Agreement for a
period of thirty (30) continuous days following the receipt of written notice of such failure to perform from the Company; or (vii)
failure to comply with the Company’s published policies or rules, as they may be in effect from time to time during the term
of the CFO‘s engagement and which are consistent with this Agreement for a period of thirty (30) continuous days following
the receipt of written notice of such failure to comply from the Board or a committee thereof.

ii. By Company Notice.
The Company may immediately terminate this Agreement and CFO’s engagement with the Company at any time for any reason not
included in the definition of Good Cause by giving CFO written notice of such termination (“Company Notice Termination“).
Such written notice will contain the effective date of the termination and requires a notice period of two weeks (14 days). During
the notice period, CFO will be compensated with base salary and bonus with continuation of all benefits but is required to use
any unused vacation time.

b. Death or Disability.
This Agreement and CFO‘s engagement with the Company will terminate immediately upon the death or Total Disability of CFO
(“Death or Disability Termination“). The term “Total Disability“ for purposes of this Agreement
shall mean that CFO has been unable to perform his essential duties and responsibilities (even with reasonable accommodation) under
this Agreement for a period of three (3) consecutive months during the Term of this Agreement by reason of CFO‘s mental or
physical disability.

c. By CFO.

i. For Good Reason.
CFO may terminate this Agreement and his engagement by the Company at any time for Good Reason (“Good Reason Termination“).
The term “Good Reason“ for purposes of this Agreement means the Company‘s failure to comply in any material respect
with the terms of this Agreement, which failure is not corrected by the Company within thirty (30) days after receiving written
notice of such failure from CFO.

ii. By CFO Notice.
CFO may terminate this Agreement and CFO’s engagement with the Company for any reason not included in the definition of Good
Reason by giving the Company two weeks (14 days) prior written notice of such termination (“CFO Notice Termination“).During
the notice period, CFO will be compensated with base salary and with continuation of all benefits but is required to use any unused
vacation time.

3.2 Results of Termination.

a. Good Cause Termination and
CFO Notice Termination. If this Agreement and CFO‘s engagement with the Company are terminated (i) by Good Cause Termination
or (ii) by CFO Notice Termination, CFO‘s compensation and benefits hereunder will terminate effective as of the date his
engagement so terminates; provided, however that CFO shall be entitled to receive any accrued but unpaid salary and any accrued
but unused vacation and sick leave. After such termination, CFO will be eligible to receive only whatever benefits are payable
as of the date of his termination under the terms of the benefit plans or programs, if any, in which CFO was participating.

b. Company Notice Termination
and Good Reason Termination. If this Agreement and CFO‘s engagement with the Company are terminated by Company Notice
Termination or for Good Reason Termination, the Company will pay CFO his regular salary until the later of (i) the end of the Term,
and (ii) the date six months from the date of the termination of CFO’s engagement and shall provide health insurance coverage
through the end of the Term.

c. Death or Disability Termination.
If this Agreement and CFO‘s engagement with the Company are terminated by Death or Disability Termination, the Company will
pay CFO (or his estate) compensation in the same amount and for the same period as called for in paragraph (b) above in the case
of Company Notice Termination or for Good Reason Termination.

4. Trade Secrets and Confidential
Information

4.1 Acknowledgment. CFO acknowledges
that during the course of his engagement with the Company he will receive and will have access to Confidential Information and
Trade Secrets of the Company, as defined hereinafter, including but not limited to confidential and secret business and marketing
plans, technical data, strategies, and studies, detailed customer and/or client lists and information relating to the operations
and business requirements of those customers and/or clients. Accordingly, CFO is willing to enter into the covenants contained
in this Agreement in order to provide the Company with what he considers to be reasonable protection for its interests.

4.2 Trade Secrets.

a. The term “Trade Secret“
as used in this Agreement means information including, but not limited to, technical or non-technical data,, a formula, a pattern,
a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans,
or a list of actual or potential customers or suppliers, which is intended for use in a trade or business and is not commonly known
by or available to the public and which information:

i. derives economic value, actual
or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can
obtain economic value from its disclosure or use; and

ii. is the subject of reasonable
efforts by the Company to maintain its secrecy or confidentiality.

b. In consideration of the Company’s
engagement of CFO pursuant to this Agreement, CFO agrees and covenants that, both during his engagement by the Company and after
the termination of his engagement, CFO will not directly or indirectly use or disclose (whether on his own behalf or on behalf
of any other person, corporation, partnership, venture, or any other entity or form of business), except as authorized by the Company
in connection with the performance of CFO‘s duties, any Trade Secret that CFO may have or acquire during the Term of this
Agreement for so long as the such information remains a Trade Secret.

4.3 Confidential Information.

a. The term “Confidential
Information” as used in this Agreement means any secret, confidential, or proprietary information of the Company, including
information received by the Company or CFO from any customer or client or potential customer or client of the Company, not otherwise
included in the definition of Trade Secret. The term Confidential Information does not include information that has become generally
available to the public by the act of one who has the right to disclose such information without violating any right of the Company
or customer or client to which such information pertains or otherwise enters the public domain through no fault of CFO.

b. In consideration of the Company‘s
engagement of CFO pursuant to this Agreement, CFO agrees that, during his engagement by the Company and for a period of three years
after termination of his engagement, CFO will not directly or indirectly use or disclose (whether on his own behalf or on behalf
of any other person, corporation, partnership, venture, or any other entity or form of business), except as authorized by the Company
in connection with the performance of CFO‘s duties, any Confidential Information that CFO may have or acquire (whether or
not developed or compiled by CFO and whether or not CFO bas been authorized to have access to such Confidential Information) during
his engagement with the Company. This Section 4.3(b) shall not apply to any Confidential Information (i) that the Company has agreed
in writing that CFO may disclose, subject to the terms of the Company‘s agreement, or (ii) that CFO is required to disclose
by law; provided, however, CFO shall give the Company reasonable notice prior to such disclosure.

CFO understands and agrees that nothing
contained herein shall be deemed a waiver, modification, or limitation of any rights the Company may have under applicable federal,
state, or local laws relating to the protection of trade secrets or confidential information.

5. Protective Covenants

5.1 Acknowledgment. The Company
is primarily engaged in the business of developing and marketing services that relate to telemedecine (the “Company’s
Business”). The Company anticipates engaging in the Company‘s Business throughout the United States (the “Territory”).
CFO acknowledges that as a result of his senior management position, CFO‘s duties and responsibilities under this Agreement
will span throughout the Territory. CFO further acknowledges that the Company‘s customer and/or client contacts and relations
are established and maintained at great expense and that CFO will, by virtue of his engagement with the Company, have unique and
extensive exposure to and personal contact with the Company’s customers and/or clients and that he will be able to establish
a unique relationship with those customers and/or clients. CFO acknowledges that the Company also has a legitimate interest in
protecting its valuable Confidential Information and Trade Secrets, to which CFO will have access. Finally, CFO acknowledges that
due to the highly technical nature of the Company‘s Business and due to his special knowledge, training, and experience,
the services he will provide the company are unique and extraordinary and that the loss of those services to the Company would
be impossible to replace and would cause the Company irreparable harm. The Company acknowledges that it may only enforce the protective
covenants if it is not in material breach of this Agreement. CFO acknowledges that a termination by Company Notice during the Term
shall not be considered in any case a breach of this Agreement.

 

5.2 Non-Solicitation and Non-Competition.
In consideration of the Company‘s engagement of CFO pursuant to this Agreement, and in order to protect the Company from
unfair competition, CFO covenants and agrees to the following:

a. During CFO‘s engagement
with the Company CFO will not:

			(i) solicit or attempt to solicit any customer and/or client or actively sought prospective client
and/or customer of the Company for any person or entity other than Company during his engagement with the Company, or

			(ii) hire (except on behalf of the Company) or solicit or encourage to leave the engagement or
other service of the Company any employee or independent contractor of the Company (except in connection with the business and
affairs of the Company).

b. For a period of two (2) years
after the termination of his engagement for any reason, CFO will not, for the purpose of competing with the Company in the Company’s
business (whether on his own behalf or on behalf of any other person, corporation, partnership, venture, or any other entity or
form of business), directly or indirectly solicit or attempt to solicit any customer and/or client of the Company within the Territory.

c. For a period of two (2) years
after the termination of CFO‘s engagement for any reason, CFO will not, for any reason (whether on CFO‘ s own behalf
or on behalf of any other person, corporation, partnership, venture, or any other entity or form of business), directly or indirectly
solicit or encourage to leave engagement or other service of the Company any employee or independent contractor of the Company
with whom CFO had material business contact any time during the twelve (12) months prior to such termination.

d.For a period of two (2)
years after the termination of his engagement for any reason, CFO will not compete with the Company in the Territory (whether on
his own behalf or on behalf of any other person, corporation, partnership, venture, or any other entity or form of business), directly
or indirectly.

This section 5.2 will cease to apply
if the Company defaults in its obligations to provide salary as provided in section 2.1 or severance pay or health insurance coverage
as provided in section 3.2(b).

6. Reasonable Restrictions

CFO acknowledges and confirms that the
restrictions and covenants contained in Sections 4 and 5 are reasonably necessary to protect the good will and legitimate business
interests of the Company, are not overbroad, overlong, or unfair (including in duration and scope), and are not the result of overreaching,
duress, or coercion of any kind. CFO further acknowledges and confirms that his full, uninhibited, and faithful observance of each
of the covenants contained in Sections 4 and 5 will not cause him any undue hardship, financial, or otherwise, and that enforcement
of each of the covenants contained herein will not impair his ability to obtain engagement commensurate with his abilities and
on terms fully acceptable to him or otherwise to obtain income required for him and his family‘s comfortable support and
the satisfaction of the needs of his creditors. CFO acknowledges and confirms that his special abilities and knowledge of the Company‘s
Business are such that it would cause the Company serious, irreparable injury, or loss if he were to use such abilities and knowledge
to the benefit of a competitor or were to otherwise violate these covenants. CFO further acknowledges that the restrictions contained
in Sections 4 and 5 are intended to be, and shall be, for the benefit of and shall be enforceable by, the Company‘s successors
and assigns.

7. Reformation

If any of the covenants or promises of
this Agreement, including but not limited to the covenants in Sections 4 and 5, are determined by any court of law or equity, with
jurisdiction over this matter, to be unreasonable or unenforceable, in whole or in part, as written, the parties hereby consent
to and affirmatively request that said court reform the covenant or promise so as to be enforceable to the maximum extent permitted
by law and that said court enforce the covenant or promise as reformed.

8. Legal and Equitable Remedies

CFO agrees that for any breach or threatened
breach of any of the provisions of this Agreement, a restraining order and/or an injunction may issue against CFO to prevent or
restrain any such breach, in addition to any other rights the Company may have.

9. No Prior Commitments

CFO represents and warrants that he (i)
will not use or disclose any trade secrets or other protected information of any other person or entity while performing his duties
under this Agreement; (ii) does not have any agreements with any other person or entity that conflict in any way with CFO’s
obligations to the Company under this Agreement; and (iii) does not have any relationships or commitments which would materially
interfere with his obligations to the Company under this Agreement.

 

10. Ownership of Inventions 

10.1 Disclosure. CFO acknowledges
and agrees that he will be employed by the Company in a position which could provide the opportunity for conceiving and/or reducing
to practice developments, discoveries, methods, processes, designs, inventions, ideas, or improvements (hereinafter collectively
called “Work Product”). Accordingly, CFO agrees to promptly report and disclose to the Company in writing all
Work Product conceived, made, implemented, or reduced to practice by CFO, whether alone or acting with others, during CFO‘s
engagement by the Company, that are developed (i) on the Company’s time, or (ii) while utilizing, directly or indirectly,
the Company‘s equipment, supplies, facilities, or trade secret information. CFO acknowledges and agrees that all Work Product
is the sole and exclusive property of the Company. CFO agrees to assign, and hereby automatically assigns, without further consideration,
to the Company any and all rights, title, and interest in and to all Work Product; provided, however that this Section 10.1
shall not apply to any Work Product for which no equipment, supplies, facilities, or trade secret information of the Company was
used and which was developed entirely on CFO’s own time, unless the Work Product (i) relates directly to the Company’s
Business or its actual or demonstrably anticipated research or development, or (ii) results from any work performed by CFO for
the Company during the Term. The Company, its successors and assigns, shall have the right to obtain and hold in its or their own
name copyright registrations, trademark registrations, patents and any other protection available to the Work Product.

10.2 Cooperation. CFO agrees
to perform, upon the reasonable request of the Company, during or within two (2) years after engagement, such further acts as may
be reasonably necessary or desirable to transfer, perfect, and defend the Company‘s ownership of the Work Product, including
but not limited to: (i) executing, acknowledging, and delivering any requested affidavits and documents of assignment and conveyance;
(ii) assisting in the preparation, prosecution, procurement, maintenance, and enforcement of all copyrights and/or patents with
respect to the Work Product in any countries; (iii) providing testimony in connection with any proceeding affecting the right,
title, or interest of the Company in any Work Product; and (iv) performing any other acts deemed necessary or desirable to carry
out the purposes of this Agreement. The Company shall reimburse all reasonable out-of-pocket expenses incurred by CFO at the Company’s
request in connection with the foregoing. If however, the CFO is requested to perform any of the above actions after termination
of engagement with the Company, such requested action shall not unduly infringe on CFO‘s ability to fulfil his business duties
and responsibilities to his new employer.

11. Company Property

All the Company’s property, equipment,
funds, books, records, files, memoranda, reports, lists, drawings, plans, sketches, documents, computer files, Trade Secrets, Confidential
Information, Work Product, and other material (together with all copies thereof), which CFO shall use, prepare, or come in contact
with or possession of during the course of, or as a result of, his engagement shall, as between the parties hereto, remain the
sole property of the Company. Upon the termination of this Agreement or upon the prior demand of the Company, CFO shall immediately
return all such property or materials and delete permanently any soft copy thereof on any media that is subject to his control
and thereafter shall not remove or cause to be removed such materials from the premises of the Company. CFO recognizes that the
unauthorized taking of any of the Company’s property may be a crime under applicable state law and may result in criminal
and/or civil liability for CFO.

12. Miscellaneous

12.1 Assignment. This Agreement
is for the personal services of CFO, and the rights and obligations of CFO under this Agreement are not assignable or delegable
in whole or in part by CFO without the prior written consent of the Company. This Agreement is assignable in whole or in part to
any parent, subsidiary, or affiliate of the Company or to any successor to the Company, whether by merger, consolidation, sale
of stock, sale of assets or otherwise; provided that the Company shall also remain liable to CFO for any failure to perform by
the assignee.

12.2 Applicable Law. This
Agreement has been entered into in and shall be governed by and construed under the laws of The Commonwealth of Massachusetts.

12.3 Consent to Jurisdiction.
CFO consents, and waives any objection, to personal jurisdiction and venue in the federal and state courts having jurisdiction
in Boston, Massachusetts in any action by the Company to enforce this Agreement or an arbitration decision related to this Agreement.

12.4 Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and
the same instrument.

12.5 Headings and Captions.
The headings and captions used in this Agreement are for convenience of reference only, and shall in no way define, limit, expand
or otherwise affect the meaning or construction of any provision of this Agreement.

12.6 Attorneys’ Fees.
Each party hereto acknowledges and agrees that it shall be liable to the other party hereto for reasonable costs and attorneys’
fees incurred in any action under this Agreement to the extent that the other party is the prevailing party.

12.7 Modification. Except
as provided in Section 7, no provision of this Agreement may be amended, changed, altered, modified, or waived except in writing
signed by CFO and an officer of the Company, which writing shall specifically reference this Agreement and the provision which
the parties intend to waive or modify.

12.8 Severability. Should
any provision of this Agreement be declared or determined by any court of competent jurisdiction to be unenforceable or invalid
for any reason, the validity of the remaining parts, terms or provisions of this Agreement shall not be affected thereby and the
invalid or unenforceable part, term or provision shall be deemed not to be a part of this Agreement. This Section 12.8 shall not
apply to any Section which is reformed pursuant to Section 7.

12.9 Waiver. The waiver by
any party to this Agreement of a breach of any of the provisions of this Agreement shall not operate or be construed as a waiver
of any subsequent or simultaneous breach of the same or different provisions.

12.10 Jointly Drafted. The
parties and their respective counsel have participated jointly in the negotiation and drafting of this Agreement. In the event
that an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
of the provisions of this Agreement.

12.11 Survival. Any provision
of this Agreement which is expressly or by implication intended to survive the termination of this Agreement, including Sections
4, 5, 6, 7, 8, 10, 11, and 12 shall survive and remain in effect after the termination of this Agreement.

12.12 No Third-Party Beneficiaries.
Except as provided in Section 12.1 and except for the heirs, executors, administrators, personal representatives, successors, and
permitted assigns of CFO, nothing herein, expressed or implied, is intended or will be construed to confer upon or give to any
person, firm, corporation, or legal entity, other than the parties and any parent, subsidiary, affiliate, or successor of the Company,
any rights, remedies or other benefits under or by reason of this Agreement.

12.13 Notices. All notices,
communications and deliveries hereunder shall be made in writing signed by or on behalf of the party making the same and shall
be delivered personally or by telecopy transmission or sent by registered or certified mail (return receipt requested) or by any
national overnight courier service (with postage and other fees prepaid) as follows:

 

If to the Company:

CEO

American Doctors Online Inc.

200 Mill Road, suite 350A

Fairhaven, MA 02719

 

If to the CFO:

Mr. Barry Hollander

319 Clematis Street, Suite 400

West Palm Beach, FL. 33401

 

or to such other representative or at
such other address of a party as such party hereto may furnish to the other parties in writing. Any such notice, communication
or delivery shall be deemed given or made (a) on the date of delivery if delivered in person (by courier service or otherwise),
(b) upon transmission by facsimile if receipt is confirmed by telephone, provided transmission is made during regular business
hours, or if not, the next business day, or (c) on the fifth (5th) business day after it is mailed by registered or
certified mail.

12.15 Understanding. CFO herewith
covenants and agrees that he has read and fully understands the contents and the effect of this Agreement. CFO warrants and agrees
that he has had a reasonable opportunity and been advised in writing to seek the advice of an attorney as to such content and effect.
CFO accepts each and all of the terms, provisions, and conditions of this Agreement, and does so voluntarily and with full knowledge
and understanding of the contents, nature, and effect of this Agreement.

 

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the date first above written.Exhibit 10.6 

 

PATENT
PURCHASE AGREEMENT 

This
PATENT PURCHASE AGREEMENT (the "Agreement") is made and entered into
this   23rd   day of October 2013, by and between American Doctors Online, Inc., a Delaware corporation ("ADOL"
or the "Company"), and Dr. Paul Bulat (the "Assignor").

RECITALS

WHEREAS, Assignor owns the patent
rights set forth on Schedule 1 (collectively, the "New Patent Rights"); and

WHERAS,
Assignor has previously assigned the patent rights identified on Schedule 2 (the “Prior Patents”) to the Company
but believes that the consideration that he has received for those patent rights was inadequate;

WHEREAS,
Assignor desires, subject only to receiving an adjustment to the consideration previously paid for the Prior Patents, to assign
the entire right, title and interest in and to the New Patent Rights, and Assignee desires to acquire the entire right, title and
interest in and to the New Patent Rights; and

WHEREAS,
ADOL has filed with the Secretary of State of Delaware a certificate of designation for its Series A Convertible Preferred Stock
in substantially the form presented to Assignor for review on October 10, 2013

WHEREAS, ADOL is willing
to issue to Assignor upon execution of the patent assignment attached hereto as Exhibit A 3,500,000, (Three
Million Five Hundred Thousand) shares of the Company's Series A Convertible Preferred; and

WHEREAS, the Assignor has
agreed that this consideration will be sufficient to compensate him fairly for the New Patent Rights and to remedy any perceived
unfairness in connection with the consideration paid for the Prior Patents;

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties
mutually agree as follows:

ASSIGNMENT AND AGREEMENT

		1.	Assignment. Assignor hereby agrees to assign and transfer to
ADOL the entire right, title and interest in and to the New Patent
Rights as listed in Schedule 1 pursuant to an executed, notarized assignment in the form set forth at Exhibit A.

		2.	Consideration. In consideration of
the New Patent Rights and the further assurances of Assignor provided herein, ADOL shall issue to Assignor, promptly upon receipt
of the executed assignment in the form of Exhibit A, 3,500,000, (Three
Million Five Hundred Thousand) shares of the Company's Series A Convertible Preferred Stock, which shares shall be duly issued,
fully-paid and non-assessable.

		3.	Further Cooperation. At the reasonable request of ADOL, Assignor
will execute and deliver such other instruments and do and perform such other acts and things as may be necessary or desirable
for effecting completely the consummation of the transactions contemplated hereby, including, without limitation, execution, acknowledgment,
and recordation of other such papers, as necessary or desirable for fully perfecting and conveying unto ADOL the benefit of the
transaction contemplated hereby. To the extent that any conception and reduction to practice information is not provided to ADOL
at the Closing, Assignor shall promptly respond to ADOL's requests for any such additional information that may exist, if needed
by ADOL in connection with the prosecution and enforcement of the Patents. 

		4.	Conduct; Release of Claims. Assignor shall not engage in any
act or conduct, or omit to perform any necessary act, the result of which would invalidate any portion of any of the Patents or
render any portion of them unenforceable. Assignor agrees that the consideration to be paid at the Closing represents adequate
consideration not only for the New Patent Rights, but also for any shortcoming in the consideration paid for the Prior Patents.
Assignor therefore surrenders any claim he might have regarding the consideration paid for the Prior Patents and releases ADOL
from any and all claims arising from the transactions by which the Prior Patents were assigned to ADOL.

		5.	REPRESENTATIONS AND WARRANTIES OF ASSIGNOR Assignor hereby represents
and warrants to ADOL as follows that as of the Closing:

		5.1.	Authority. Assignor is a natural person and the sole inventor
and owner of the Patents. Assignor has the full power and authority and has obtained all third party consents, approvals, and/or
other authorizations required to enter into this Agreement and to carry out his obligations hereunder, including, without limitation,
the assignment of the New Patent Rights to ADOL.

		5.2.	Title and Contest. Assignor owns all right, title, and interest
to the New Patent Rights, including, without limitation, all right, title, and interest to sue for infringement of the Patents.
The New Patent Rights are free and clear of all liens, claims, mortgages, security interests or other encumbrances, and restrictions.
There are no actions, suits, investigations, claims, or proceedings threatened, pending, or, to Assignor's knowledge, in progress
relating in any way to the New Patent Rights. There are no existing binding contracts, agreements, options, commitments, proposals,
bids, offers, or rights with, to, or in any person to acquire any of the New Patent Rights. Assignor does not plan to and, in any
event, will not seek protection under state, federal or international laws concerning bankruptcy, insolvency, reorganization, moratorium
or other similar laws affecting or relating generally to creditors’ rights at any time between the Effective Date and a period
of one hundred twenty (120) days following the Closing Date.

		5.3.	Existing Licenses. After the Effective Date, none of Assignor
or his affiliates, any prior owner, or any inventor will retain any rights or interest in the New Patent Rights. There are no existing
licenses to the New Patent Rights.

		5.4.	Validity and Enforceability. None of the Patents has ever
been found invalid, unpatentable, or unenforceable for any reason in a final decision in any administrative, arbitration, judicial
or other proceeding. To the extent "small entity" fees at the time of such payment were paid to the United States Patent
and Trademark Office for any Patent, such reduced fees were then appropriate because the payor qualified to pay "small entity"
fees and specifically had not licensed rights in any Patent to an Entity that was not a "small entity." 

		5.5.	Conduct. Assignor or its agents or representatives have not
engaged in any act or conduct that constitutes patent misuse or misrepresented Assignor's or its Affiliates' patent rights to a
standard-setting organization with respect to the Patents. There is no obligation imposed by a standards-setting organization on
Assignor to license any of the Patents on particular terms or conditions.

		5.6.	Fees. All maintenance fees, annuities, and the like due or
payable on the Patents have been timely paid. For the avoidance of doubt, such timely payment includes payment of any maintenance
fees for which the fee is payable (e.g., the fee payment window opens) even if the surcharge date or final deadline for payment
of such fee would be in the future. 

		6.	.Miscellaneous. This Agreement shall
be binding upon the parties hereto and their successors. This Agreement
will be governed by and construed under the laws of the Commonwealth
of Massachusetts, U.S.A., without regard to its conflicts-of-law principles. The provisions
of this Agreement are severable. If any provision of this Agreement is held to be invalid,
illegal or unenforceable, the validity, legality or enforceability of the remaining provisions
will in no way be affected or impaired thereby. The parties agree that the recitals contained
herein are incorporated by reference into this Agreement as representations of the party described in the recitals. 

IN
WITNESS WHEREOF, the undersigned has executed
this Agreement as of the   23   day of October 2013.

    	 

    	 

    

SCHEDULE
1 

DESCRIPTION OF NEW PATENT RIGHTS

 

U.S. Patent application serial no. 12/870,341 filed 8/27/2010 entitled
HEALTH CARE TRIAGE VIDEOCONFERENCING SYSTEM

 

U.S. Patent application serial no. 61/237,444 filed 8/27/2009 entitled
HEALTH CARE TRIAGE VIDEOCONFERENCING SYSTEM 

    	 

    	 

    

 

SCHEDULE
2 

PRIOR PATENTS AND PATENT APPLICATIONS

 

U.S. Patent application serial no. 09/855,738 filed May 14, 2001,
now U.S. Patent No. 6,638,218, entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, DIAGNOSIS, AND TREATMENT OVER A NETWORK

 

U.S. Patent application serial no. 10/694,519 filed October 27,
2003, now U.S. Patent No. 7,011,629, entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, TREATMENT, AND ASSISTANCE OVER
A NETWORK

 

U.S. Patent application serial no. 11/321,332 filed December 29,
2005, now U.S. Patent No. 7,691,059, entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, TREATMENT, AND ASSISTANCE OVER
A NETWORK

 

U.S. Patent application serial no. 11/409,713 filed April 24, 2006,
entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, TREATMENT, AND ASSISTANCE OVER A NETWORK

 

U.S. Patent application serial no. 12/273,065 filed November 18,
2008, now U.S. Patent No. 7,970,633, entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, TREATMENT, AND ASSISTANCE OVER
A NETWORK

 

U.S. Patent application serial no. 13/952,913 filed July 29, 2013,
entitled SYSTEM AND METHOD FOR DELIVERING MEDICAL EXAMINATION, TREATMENT, AND ASSISTANCE OVER A NETWORK

 

 

 

 

    	 

    	 

    

 

Exhibit A

 

ASSIGNMENT

 

ASSIGNOR:  Paul I. Bulat

 

ASSIGNEE:   American
Doctors Online, Inc.

200 Mill Road, Suite 250A

Fairhaven, MA 02719

 

 

STATE OF INCORPORATION OF ASSIGNEE:
 Delaware

 

TITLE:HEALTH CARE TRIAGE
VIDEOCONFERENCING SYSTEM

 

ATTORNEY DOCKET: 2551/106

 

APPLICATION NO.:See Schedule
1 hereto

 

INITIAL FILING DATE:August 27, 2009

 

Assignor is an inventor
of a certain new and useful invention (the "Invention") described in United States patent applications (the "Applications")
bearing the above attorney docket number and having the above title. The earliest filed Application has a Patent and Trademark
Office filing date as indicated above.

 

For valuable consideration, receipt of
which is acknowledged, Assignor hereby assigns to Assignee (which term shall include Assignee's successors and assigns), all of
Assignor's right, title and interest in the Invention, including the right to sue for past infringement, all improvements therein,
the Application and all priority rights arising therefrom, and any patents, and any reissues and extensions thereof, which issue
in any country upon any patent applications which correspond with any of the following: the Application; any application that claims
priority from the Application (including as a divisional, continuation-in-whole or continuation-in-part, or as an application claiming
priority from a provisional application); or any application based in whole or in part on any of the foregoing.

 

Each Assignor further agrees that such
Assignor and Assignor's heirs and legal representatives will, without further consideration, cooperate with Assignee in the prosecution
of all of the above applications, execute, verify, acknowledge and deliver all such further papers, including applications for
patents and for reissues and extensions therefor, and instruments of assignment and transfer thereof, and will communicate any
facts known to Assignor relating to the Invention, to obtain or maintain or enforce patents for the Invention and improvements
therein in any and all countries and to vest title thereto in Assignee. Each Assignor further agrees that such Assignor will, without
further compensation to Assignor during the term of such Assignor's employment by Assignee and thereafter for reasonable compensation
as determined by Assignee, perform such other acts as may be reasonably required when requested by Assignee, including attending
depositions, preparing and executing declarations and affidavits and testifying as a witness, to obtain or maintain or enforce
patents for the Invention and improvements therein in any and all countries and to vest title thereto in Assignee.

IN WITNESS WHEREOF, each Assignor hereby
executes this instrument on the date set forth below.

 

    	 

    	 

    

 

SCHEDULE
1 

PATENT APPLICATIONS BEING ASSIGNED

 

U.S. Patent application serial no. 12/870,341 filed August 27, 2010
entitled HEALTH CARE TRIAGE VIDEOCONFERENCING SYSTEM

 

U.S. Patent application serial no. 61/237,444 filed August 27, 2009
entitled HEALTH CARE TRIAGE VIDEOCONFERENCING SYSTEM

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]